Dose-Ranging Proof of Concept Study of BIIB033 in Relapsing MS

• Research type

  Research Study

• Full title

  A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects with Relapsing Forms of Multiple Sclerosis When Used Concurrently with Avonex®

• IRAS ID

  131666

• Contact name

  Benjamin Turner

• Contact email

  Benjamin.Turner@bartshealth.nhs.uk

• Sponsor organisation

  Biogen Idec Research Limited

• Eudract number

  2011-006262-40

• ISRCTN Number

  xx

• REC name

  London - Westminster Research Ethics Committee

• REC reference

  13/LO/1019

• Date of REC Opinion

  24 Sep 2013

• REC opinion

  Further Information Favourable Opinion